Remove 2022 Remove FDA Remove Pharmaceutical manufacturing
article thumbnail

FDA releases analysis on drug product quality in 2022

European Pharmaceutical Review

The Office of Pharmaceutical Quality (OPQ) in the US Food and Drug Administration (FDA)’s Center Pharmaceutical Quality for Drug Evaluation and Research (CDER) has released its 2022 annual report analysing drug manufacturers and their products. percent) to be noncompliant.

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

The recent dip in transactional activity in 2022 and the increased borrowing costs through interest rate pressure have put deals under ever-increasing scrutiny. These teams will include experts in regulatory, GMP compliance and quality systems, often including ex-FDA and MHRA inspectors and industry experts.

Pharma 119
article thumbnail

New Research Reveals Three Ways Pharma Can Better Prioritize Payer Audiences

PM360

The pandemic had a huge impact on the way population health decision-makers (PHDMs) navigate our industry, and now that it’s clear many of these shifts are here to stay, pharmaceutical manufacturers need to adjust accordingly. New Drug Therapy Approvals 2022.” That’s why an evolution of communications strategies is necessary.

Pharma 92
article thumbnail

Strategies for Combination Therapy in Oncology: Part One – Business as Usual

PM360

Combination Therapy in Oncology Combination therapies comprising two or more therapeutic agents have become a cornerstone of oncology management and are increasingly a development focus for the pharmaceutical industry. Food and Drug Administration (FDA) oncology approvals were for drugs used in combination. 3 (2022): e222265.

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

Pharmaceutical manufacturing Oligonucleotides Last month, the Centre for Process Innovation (CPI) announced a new Scotland-based manufacturing facility focusing on oligonucleotide therapeutics. ZUMA-7 is the first and largest Phase III study of any CAR T-cell therapy, with the longest follow-up.

article thumbnail

Non-stop investment from CMOs and US Government into continuous manufacturing

Pharmaceutical Technology

Abzena is expected to open a continuous manufacturing facility for biologics in Sanford, North Carolina, in Q4 2022. National Resilience (San Diego, California) announced on 6 June that it had raised $625m in series D financing, which will be spent in part on continuous manufacturing for biologics.